Skip to main content
SpringerLink
Log in

Insomnie, Hypersomnie, Parasomnie

Schlafstörungen beim idiopathischen Parkinson-Syndrom

  • zertifizierte Fortbildung
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

Zusammenfassung

Viele Patienten mit idiopathischem Parkinson-Syndrom leiden unter nicht motorischen Symptomen wie Schlafstörungen, die zu Einschränkungen der Lebensqualität führen. Gehäuft treten Insomnien, eine erhöhte Tagesschläfrigkeit und die REM-Schlaf-Verhaltensstörung auf. Zudem leiden auch Parkinson-Patienten unter primären Schlafstörungen wie schlafbezogenen Atmungsstörungen und dem Restless-Legs-Syndrom. Zur Therapie der Schlafstörungen sollten zunächst eine Optimierung der Behandlung der Grunderkrankung sowie spezielle nicht medikamentöse und medikamentöse Verfahren angewendet werden

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Lang AE, Lozano AM. Parkinson’s disease. Second of two parts. The New England journal of medicine. 1998;339(16):1130–43.

    Article  CAS  PubMed  Google Scholar 

  2. Lang AE, Lozano AM. Parkinson’s disease. First of two parts. The New England journal of medicine. 1998;339(15):1044–53.

    Article  CAS  PubMed  Google Scholar 

  3. Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with Parkinson’s disease. A self-reported, community-based survey. Sleep medicine. 2002;3(2):147–9.

    Article  PubMed  Google Scholar 

  4. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society. 1998;13(6):895–9.

    Article  CAS  Google Scholar 

  5. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society. 1990;5(4):280–5.

    Article  CAS  Google Scholar 

  6. Kalaitzakis ME, Gentleman SM, Pearce RK. Disturbed sleep in Parkinson’s disease: anatomical and pathological correlates. Neuropathology and applied neurobiology. 2013;39(6):644–53.

    Article  CAS  PubMed  Google Scholar 

  7. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of aging. 2003;24(2):197–211.

    Article  PubMed  Google Scholar 

  8. Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson’s disease. Annals of neurology. 2008;64(5):485–91.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta neuropathologica. 2008;116(1):1–16.

    Article  CAS  PubMed  Google Scholar 

  10. Willison LD, Kudo T, Loh DH, Kuljis D, Colwell CS. Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson’s disease: insights from a transgenic mouse model. Experimental neurology. 2013;243:57–66.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bolitho SJ, Naismith SL, Rajaratnam SM, Grunstein RR, Hodges JR, Terpening Z, et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep medicine. 2014;15(3):342–7.

    Article  CAS  PubMed  Google Scholar 

  12. Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA neurology. 2014;71(5):589–95.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA neurology. 2014;71(4):463–9.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Shochat T, Loredo J, Ancoli-Israel S. Sleep Disorders in the Elderly. Current treatment options in neurology. 2001;3(1):19–36.

    Article  CAS  PubMed  Google Scholar 

  15. Lee MA, Prentice WM, Hildreth AJ, Walker RW. Measuring symptom load in Idiopathic Parkinson’s disease. Parkinsonism & related disorders. 2007;13(5):284–9.

    Article  CAS  Google Scholar 

  16. Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Movement disorders: official journal of the Movement Disorder Society. 2007;22(11):1623–9.

    Article  Google Scholar 

  17. van Hilten B, Hoff JI, Middelkoop HA, van der Velde EA, Kerkhof GA, Wauquier A, et al. Sleep disruption in Parkinson’s disease. Assessment by continuous activity monitoring. Archives of neurology. 1994;51(9):922–8.

    Article  PubMed  Google Scholar 

  18. Wetter TC, Collado-Seidel V, Pollmacher T, Yassouridis A, Trenkwalder C. Sleep and periodic leg movement patterns in drug-free patients with Parkinson’s disease and multiple system atrophy. Sleep. 2000;23(3):361–7.

    CAS  PubMed  Google Scholar 

  19. Askenasy JJ, Yahr MD. Reversal of sleep disturbance in Parkinson’s disease by antiparkinsonian therapy: a preliminary study. Neurology. 1985;35(4):527–32.

    Article  CAS  PubMed  Google Scholar 

  20. Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002;58(3):341–6.

    Article  PubMed  Google Scholar 

  21. Ongini E, Caporali MG, Massotti M. Stimulation of dopamine D-1 receptors by SKF 38393 induces EEG desynchronization and behavioral arousal. Life sciences. 1985;37(24):2327–33.

    Article  CAS  PubMed  Google Scholar 

  22. Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in Parkinson’s disease. Annals of neurology. 1989;26(1):41–6.

    Article  CAS  PubMed  Google Scholar 

  23. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clinical neuropharmacology. 1988;11(6):512–9.

    Article  CAS  PubMed  Google Scholar 

  24. Monaca C, Ozsancak C, Jacquesson JM, Poirot I, Blond S, Destee A, et al. Effects of bilateral subthalamic stimulation on sleep in Parkinson’s disease. Journal of neurology. 2004;251(2):214–8.

    Article  CAS  PubMed  Google Scholar 

  25. Iranzo A, Valldeoriola F, Santamaria J, Tolosa E, Rumia J. Sleep symptoms and polysomnographic architecture in advanced Parkinson’s disease after chronic bilateral subthalamic stimulation. Journal of neurology, neurosurgery, and psychiatry. 2002;72(5):661–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Movement disorders: official journal of the Movement Disorder Society. 2011;26(1):90–9.

    Article  Google Scholar 

  27. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet neurology. 2007;6(6):513–20.

    Article  CAS  PubMed  Google Scholar 

  28. Fernandez-Pajarin G, Sesar A, Ares B, Castro A. Evaluating the Efficacy of Nocturnal Continuous Subcutaneous Apomorphine Infusion in Sleep Disorders in Advanced Parkinson’s Disease: The APO-NIGHT Study. Journal of Parkinson’s disease. 2016;6(4):787–92.

    Article  CAS  PubMed  Google Scholar 

  29. Hogl B, Rothdach A, Wetter TC, Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson’s disease. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2003;28(10):1866–70.

    Article  CAS  Google Scholar 

  30. Brunner H, Wetter TC, Hogl B, Yassouridis A, Trenkwalder C, Friess E. Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson’s disease: effects of dopaminergic treatment. Movement disorders: official journal of the Movement Disorder Society. 2002;17(5):928–33.

    Article  Google Scholar 

  31. De Cock VC, Vidailhet M, Arnulf I. Sleep disturbances in patients with parkinsonism. Nature clinical practice Neurology. 2008;4(5):254–66.

    Article  PubMed  Google Scholar 

  32. Comella CL, Morrissey M, Janko K. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology. 2005;64(8):1450–1.

    Article  PubMed  Google Scholar 

  33. Kurtis MM, Rodriguez-Blazquez C, Martinez-Martin P, Group E. Relationship between sleep disorders and other non-motor symptoms in Parkinson’s disease. Parkinsonism & related disorders. 2013;19(12):1152–5.

    Article  Google Scholar 

  34. Vaughan CP, Juncos JL, Trotti LM, Johnson TM, 2nd, Bliwise DL. Nocturia and overnight polysomnography in Parkinson disease. Neurourology and urodynamics. 2013.

  35. Borek LL, Kohn R, Friedman JH. Mood and sleep in Parkinson’s disease. J Clin Psychiatry. 2006;67(6):958–63.

    Article  PubMed  Google Scholar 

  36. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry research. 1989;28(2):193–213.

    Article  CAS  PubMed  Google Scholar 

  37. Muntean ML, Benes H, Sixel-Doring F, Chaudhuri KR, Suzuki K, Hirata K, et al. Clinically relevant cut-off values for the Parkinson’s Disease Sleep Scale-2 (PDSS-2): a validation study. Sleep medicine. 2016;24:87–92.

    Article  PubMed  Google Scholar 

  38. Trenkwalder C, Kohnen R, Hogl B, Metta V, Sixel-Doring F, Frauscher B, et al. Parkinson’s disease sleep scale—validation of the revised version PDSS-2. Movement disorders: official journal of the Movement Disorder Society. 2011;26(4):644–52.

    Article  Google Scholar 

  39. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study. Movement disorders: official journal of the Movement Disorder Society. 2007;22(13):1901–11.

    Article  Google Scholar 

  40. Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson’s disease. Sleep medicine. 2005;6(5):459–66.

    Article  PubMed  Google Scholar 

  41. Abe K, Hikita T, Sakoda S. [A hypnotic drug for sleep disturbances in patients with Parkinson’s disease]. No to shinkei = Brain and nerve. 2005;57(4):301–5.

    PubMed  Google Scholar 

  42. Juri C, Chana P, Tapia J, Kunstmann C, Parrao T. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clinical neuropharmacology. 2005;28(4):185–7.

    Article  CAS  PubMed  Google Scholar 

  43. Silva-Batista C, Campos de Brito L, Corcos DM, Roschel H, Tulio de Mello M, Pimentel Piemonte ME, et al. Resistance Training Improves Sleep Quality In Subjects With Moderate Parkinson’s Disease. Journal of strength and conditioning research. 2016.

    Google Scholar 

  44. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study. Movement disorders: official journal of the Movement Disorder Society. 1999;14(6):922–7.

    Article  CAS  Google Scholar 

  45. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology. 2001;57(8):1392–6.

    Article  CAS  PubMed  Google Scholar 

  46. Ghorayeb I, Loundou A, Auquier P, Dauvilliers Y, Bioulac B, Tison F. A nationwide survey of excessive daytime sleepiness in Parkinson’s disease in France. Movement disorders: official journal of the Movement Disorder Society. 2007;22(11):1567–72.

    Article  Google Scholar 

  47. Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology. 2005;65(9):1442–6.

    Article  CAS  PubMed  Google Scholar 

  48. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep medicine reviews. 2005;9(3):185–200.

    Article  PubMed  Google Scholar 

  49. Rye DB. The two faces of Eve: dopamine’s modulation of wakefulness and sleep. Neurology. 2004;63(8 Suppl 3):S2–7.

    Article  PubMed  Google Scholar 

  50. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27(3):469–74.

    Article  CAS  PubMed  Google Scholar 

  51. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain: a journal of neurology. 2007;130(Pt 6):1586–95.

    Article  Google Scholar 

  52. Suzuki K, Miyamoto M, Miyamoto T, Iwanami M, Hirata K. Sleep disturbances associated with Parkinson’s disease. Parkinson’s disease. 2011;2011:219056.

    PubMed  PubMed Central  Google Scholar 

  53. Diederich NJ, Vaillant M, Mancuso G, Lyen P, Tiete J. Progressive sleep ‚destructuring‘ in Parkinson’s disease. A polysomnographic study in 46 patients. Sleep medicine. 2005;6(4):313–8.

    Article  PubMed  Google Scholar 

  54. Poryazova R, Benninger D, Waldvogel D, Bassetti CL. Excessive daytime sleepiness in Parkinson’s disease: characteristics and determinants. European neurology. 2010;63(3):129–35.

    Article  CAS  PubMed  Google Scholar 

  55. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology. 2006;67(5):853–8.

    Article  CAS  PubMed  Google Scholar 

  56. Monti JM, Hawkins M, Jantos H, D’Angelo L, Fernandez M. Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat. Psychopharmacology. 1988;95(3):395–400.

    Article  CAS  PubMed  Google Scholar 

  57. Isaac SO, Berridge CW. Wake-promoting actions of dopamine D1 and D2 receptor stimulation. The Journal of pharmacology and experimental therapeutics. 2003;307(1):386–94.

    Article  CAS  PubMed  Google Scholar 

  58. Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson’s disease: a controlled study. Movement disorders: official journal of the Movement Disorder Society. 2003;18(6):668–72.

    Article  Google Scholar 

  59. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5.

    Article  CAS  PubMed  Google Scholar 

  60. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. Journal of neurology, neurosurgery, and psychiatry. 2005;76(12):1636–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet neurology. 2013;12(11):1068–75.

    Article  CAS  PubMed  Google Scholar 

  62. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. The New England journal of medicine. 2005;353(19):2034–41.

    Article  CAS  PubMed  Google Scholar 

  63. Beebe DW, Groesz L, Wells C, Nichols A, McGee K. The neuropsychological effects of obstructive sleep apnea: a meta-analysis of norm-referenced and case-controlled data. Sleep. 2003;26(3):298–307.

    PubMed  Google Scholar 

  64. Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, Welter ML, et al. Parkinson’s disease and sleepiness: an integral part of PD. Neurology. 2002;58(7):1019–24.

    Article  CAS  PubMed  Google Scholar 

  65. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep medicine. 2003;4(2):101–19.

    Article  PubMed  Google Scholar 

  66. Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nature genetics. 2007;39(8):1000–6.

    Article  CAS  PubMed  Google Scholar 

  67. Rijsman RM, Schoolderman LF, Rundervoort RS, Louter M. Restless legs syndrome in Parkinson’s disease. Parkinsonism & related disorders. 2014;20 Suppl 1:S5–9.

    Article  Google Scholar 

  68. Bhalsing K, Suresh K, Muthane UB, Pal PK. Prevalence and profile of Restless Legs Syndrome in Parkinson’s disease and other neurodegenerative disorders: a case-control study. Parkinsonism & related disorders. 2013;19(4):426–30.

    Article  Google Scholar 

  69. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep medicine. 2004;5(3):237–46.

    Article  PubMed  Google Scholar 

  70. Moccia M, Erro R, Picillo M, Santangelo G, Spina E, Allocca R, et al. A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. Sleep. 2016;39(2):405–12.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Banno K, Delaive K, Walld R, Kryger MH. Restless legs syndrome in 218 patients: associated disorders. Sleep medicine. 2000;1(3):221–9.

    Article  CAS  PubMed  Google Scholar 

  72. Lee JE, Shin HW, Kim KS, Sohn YH. Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. Movement disorders: official journal of the Movement Disorder Society. 2009;24(4):579–82.

    Article  Google Scholar 

  73. Wong JC, Li Y, Schwarzschild MA, Ascherio A, Gao X. Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep. 2014;37(2):369–72.

    PubMed  PubMed Central  Google Scholar 

  74. Trenkwalder C, Walters AS, Hening WA, Chokroverty S, Antonini A, Dhawan V, et al. Positron emission tomographic studies in restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society. 1999;14(1):141–5.

    Article  CAS  Google Scholar 

  75. Ruottinen HM, Partinen M, Hublin C, Bergman J, Haaparanta M, Solin O, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology. 2000;54(2):502–4.

    Article  CAS  PubMed  Google Scholar 

  76. Michaud M, Soucy JP, Chabli A, Lavigne G, Montplaisir J. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. Journal of neurology. 2002;249(2):164–70.

    Article  PubMed  Google Scholar 

  77. Eisensehr I, Wetter TC, Linke R, Noachtar S, von Lindeiner H, Gildehaus FJ, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology. 2001;57(7):1307–9.

    Article  CAS  PubMed  Google Scholar 

  78. Connor JR, Wang XS, Allen RP, Beard JL, Wiesinger JA, Felt BT, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain: a journal of neurology. 2009;132(Pt 9):2403–12.

    Article  Google Scholar 

  79. Chahine LM, Ahmed A, Sun Z. Effects of STN DBS for Parkinson’s disease on restless legs syndrome and other sleep-related measures. Parkinsonism & related disorders. 2011;17(3):208–11.

    Article  CAS  Google Scholar 

  80. Peeraully T, Tan EK. Linking restless legs syndrome with Parkinson’s disease: clinical, imaging and genetic evidence. Transl Neurodegener. 2012;1(1):6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Qu S, Le W, Zhang X, Xie W, Zhang A, Ondo WG. Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. Journal of neuropathology and experimental neurology. 2007;66(5):383–8.

    Article  CAS  PubMed  Google Scholar 

  82. Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society. 2000;15(1):154–8.

    Article  CAS  Google Scholar 

  83. Koblinger K, Fuzesi T, Ejdrygiewicz J, Krajacic A, Bains JS, Whelan PJ. Characterization of A11 neurons projecting to the spinal cord of mice. PloS one. 2014;9(10):e109636.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54(8):1698–700.

    Article  CAS  PubMed  Google Scholar 

  85. Allen RP, Barker PB, Wehrl FW, Song HK, Earley CJ. MRI measurement of brain iron in patients with restless legs syndrome. Neurology. 2001;56(2):263–5.

    Article  CAS  PubMed  Google Scholar 

  86. Connor JR, Wang XS, Patton SM, Menzies SL, Troncoso JC, Earley CJ, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology. 2004;62(9):1563–7.

    Article  CAS  PubMed  Google Scholar 

  87. Schmidauer C, Sojer M, Seppi K, Stockner H, Hogl B, Biedermann B, et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Annals of neurology. 2005;58(4):630–4.

    Article  PubMed  Google Scholar 

  88. Ryu JH, Lee MS, Baik JS. Sonographic abnormalities in idiopathic restless legs syndrome (RLS) and RLS in Parkinson’s disease. Parkinsonism & related disorders. 2011;17(3):201–3.

    Article  Google Scholar 

  89. Trenkwalder C, Benes H, Grote L, Garcia-Borreguero D, Hogl B, Hopp M, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet neurology. 2013;12(12):1141–50.

    Article  CAS  PubMed  Google Scholar 

  90. Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. The New England journal of medicine. 2014;370(7):621–31.

    Article  CAS  PubMed  Google Scholar 

  91. Schenck CH, Bundlie SR, Patterson AL, Mahowald MW. Rapid eye movement sleep behavior disorder. A treatable parasomnia affecting older adults. JAMA: the journal of the American Medical Association. 1987;257(13):1786–9.

    Article  CAS  PubMed  Google Scholar 

  92. Boeve BF. REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Annals of the New York Academy of Sciences. 2010;1184:15–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Noachtar S, Eisensehr I. [REM sleep behavior disorder]. Der Nervenarzt. 2000;71(10):802–6.

    Article  CAS  PubMed  Google Scholar 

  94. Rye DB. Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep. 1997;20(9):757–88.

    CAS  PubMed  Google Scholar 

  95. Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain: a journal of neurology. 2007;130(Pt 11):2770–88.

    Article  CAS  Google Scholar 

  96. Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoriola F, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet neurology. 2006;5(7):572–7.

    Article  PubMed  Google Scholar 

  97. Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet neurology. 2013;12(5):443–53.

    Article  PubMed  Google Scholar 

  98. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep medicine. 2013;14(8):744–8.

    Article  PubMed  Google Scholar 

  100. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9(2):293–308.

    CAS  PubMed  Google Scholar 

  101. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology. 2006;66(6):845–51.

    Article  CAS  PubMed  Google Scholar 

  102. Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir JY. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Annals of neurology. 2011;69(5):811–8.

    Article  PubMed  Google Scholar 

  103. Boot BP, Boeve BF, Roberts RO, Ferman TJ, Geda YE, Pankratz VS, et al. Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. Annals of neurology. 2012;71(1):49–56.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson’s disease and controls. Brain: a journal of neurology. 2000;123 ( Pt 6):1155–60.

    Article  Google Scholar 

  105. Ferini-Strambi L. Does idiopathic REM sleep behavior disorder (iRBD) really exist? What are the potential markers of neurodegeneration in iRBD? Sleep medicine. 2011;12 Suppl 2:S43–9.

    Article  PubMed  Google Scholar 

  106. Ohayon MM, Schenck CH. Violent behavior during sleep: prevalence, comorbidity and consequences. Sleep medicine. 2010;11(9):941–6.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Gagnon JF, Bedard MA, Fantini ML, Petit D, Panisset M, Rompre S, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease. Neurology. 2002;59(4):585–9.

    Article  CAS  PubMed  Google Scholar 

  108. Zhang X, Sun X, Wang J, Tang L, Xie A. Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson’s disease: a meta and meta-regression analysis. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2016.

  109. Mahale R, Yadav R, Pal PK. Rapid eye movement sleep behaviour disorder in young- and older-onset Parkinson disease: a questionnaire-based study. Sleep medicine. 2014;15(6):642–6.

    Article  CAS  PubMed  Google Scholar 

  110. Scaglione C, Vignatelli L, Plazzi G, Marchese R, Negrotti A, Rizzo G, et al. REM sleep behaviour disorder in Parkinson’s disease: a questionnaire-based study. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2005;25(6):316–21.

    Article  CAS  Google Scholar 

  111. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. JAMA neurology. 2015;72(8):863–73.

    Article  PubMed  Google Scholar 

  112. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Movement disorders: official journal of the Movement Disorder Society. 2008;23(12):1665–72.

    Article  Google Scholar 

  113. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. REM sleep behaviour disorder in Parkinson’s disease is associated with specific motor features. Journal of neurology, neurosurgery, and psychiatry. 2008;79(10):1117–21.

    Article  CAS  PubMed  Google Scholar 

  114. Li SX, Wing YK, Lam SP, Zhang J, Yu MW, Ho CK, et al. Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK). Sleep medicine. 2010;11(1):43–8.

    Article  CAS  PubMed  Google Scholar 

  115. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Movement disorders: official journal of the Movement Disorder Society. 2007;22(16):2386–93.

    Article  Google Scholar 

  116. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep medicine. 2003;4(4):281–4.

    Article  PubMed  Google Scholar 

  117. Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology. 2003;61(10):1418–20.

    Article  CAS  PubMed  Google Scholar 

  118. Wang Y, Yang Y, Wu H, Lan D, Chen Y, Zhao Z. Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2016;12(10):1403–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Neurologie und Interdisziplinäres, Schlaflabor der Klinik für Neurologie und der Medizinischen Klinik I Universitätsklinikum Carl Gustav, Carus an der TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland

    Wiebke Schrempf

  2. Klinik und Poliklinik für Neurologie, Klinikum Carl Gustav Carus der TU Dresden, Dekan der Medizinischen Fakultät, Dresden, Deutschland

    Heinz Reichmann (Direktor)

Authors
  1. Wiebke Schrempf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heinz Reichmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wiebke Schrempf.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen. W. Schrempf hat von der Firma TEVA GmbH einen „unrestricted research grant“ für eine IIT-Studie sowie von den Firmen UCB Pharma und TEVA Unterstützung für Reisekosten- /Fortbildungen erhalten. H. Reichmann nahm an Advisory Boards teil, hielt Vorträge und erhielt Forschungsförderung durch Abbott, Abbvie, Bayer Health Care, Bial, Boehringer lngelheim, Brittania, Cephalon, Desitin, GSK, Lundbeck, Medtronic, Merck-Serono, Neuroderm, Novartis, Orion, Pfizer, TEVA, UCB Pharma, Valeant und Zambon. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schrempf, W., Reichmann, H. Schlafstörungen beim idiopathischen Parkinson-Syndrom. InFo Neurologie 19, 38–49 (2017). https://doi.org/10.1007/s15005-017-1933-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-017-1933-7

Search

Navigation